Daniel A. Haber

In metastatic breast cancer on TROP2- or HER2-targeting antibody-drug conjugates, early CTC disappearance or steep decline tracked response, while CTC epitope levels neither predicted benefit nor vanished at resistance.

This study identifies TMPO as a driver of CTC heterogeneity and metastasis in prostate cancer by enhancing survival under metabolic stress.

The paper identifies HECTD4 as a tumor and metastasis suppressor that targets COX-2 for degradation, with COX-2 stabilization driving pro-tumorigenic effects in breast cancer.

This study identifies CDKN1B as a regulator of drug-tolerant persister CTCs by preventing polyploidy after mitotic inhibitor treatment in breast cancer.

This study uses high-throughput microfluidic technology to enrich CTCs from large blood volumes, enabling detailed molecular and morphological analysis of tumor cells in metastatic cancer patients.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

The paper identifies ATRAID as a gene critical for the response to nitrogen-containing bisphosphonates, showing its role in drug efficacy and resistance in osteoporosis.

The paper analyzes rare germline variation in cancer predisposing genes across cancer patients and controls to identify shared mutation properties and candidate susceptibility genes.